Canadian Generic Market
•Download as PPT, PDF•
2 likes•791 views
The document provides an overview of the Canadian generic prescription drug market for the 12 months ending September 2007. Some key facts presented include that generics accounted for 47.6% of the overall prescription drug market by dollars. The generic market share varied regionally, ranging from 42.2% in Nunavut to 56.7% in Nova Scotia. The top 15 drug products represented 22% of the total market by dollars. The document also ranks corporations and manufacturers by their share of drugstore and hospital sales and retail prescriptions in the Canadian generic drug market.
Report
Share
Report
Share
Recommended
July 30 Webinar 3: Sharing and comparing feedback for the PMPRB Guidelines
July 30 Webinar 3: Sharing and comparing feedback for the PMPRB GuidelinesCanadian Organization for Rare Disorders
Webinar 3: Sharing and comparing feedback for the PMPRB Guidelines – July 30, 2020 at 12PM – 1PM EDT. Specialty Drugs for Hepatitis C, Multiple Sclerosis and Cancer Drove New Bran...
The unprecedented $20.2Bn increase in spending on new brands contributed 6.1% points to overall 13.1% growth in 2014.
Webinar 3: Alternative Approaches to Innovative Drug Pricing
Webinar 3: Alternative Approaches to Innovative Drug PricingCanadian Organization for Rare Disorders
The document discusses the proposed changes to Canada's Patented Medicine Prices Review Board (PMPRB) regulations and their potential impacts. It begins with concerns over implementing drastic price reductions for new prescription medicines during the COVID-19 pandemic. It then provides an overview of the webinar topics, which include perspectives on alternative drug pricing approaches and implications of the PMPRB changes. The changes would lower Canada's drug prices significantly by changing the comparator countries used to set maximum prices and introducing new factors to unilaterally set maximum rebated prices. There are concerns this could reduce patient access to innovative medicines, especially for rare diseases.Webinar 1: Has the PMPRB removed the obstacles to access in its Guidelines?
Webinar 1: Has the PMPRB removed the obstacles to access in its Guidelines?Canadian Organization for Rare Disorders
Summer 2020 PMPRB Webinar Series
Has the PMPRB removed the obstacles to access in its Guidelines? Thursday, June 25, 2020 12PM - 1PM EDTWebinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?Canadian Organization for Rare Disorders
CORD Spring 2020 Webinar Series
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?Increasing Numbers of Launches and Growth in Spending on Specialty Products i...
The specialty products share of the R&D pipeline has increased 9% in the past decade, driven by drugs targeting cancer, nervous system disorders, infectious diseases, diabetes and respiratory disorders.
Unpacking the OHIP+ pharmacare plan for kids & youth in Ontario
Listeners participated in a live panel session addressing OHIP+, the recently announced expansion of the Ontario drug program to cover young people who are younger than 25 years-old.
Webinar 1: Patients Speak Out
The document summarizes a webinar on the changes to Canada's Patented Medicine Prices Review Board (PMPRB) and its potential negative impacts. It notes that the PMPRB is implementing drastic price reductions for new drugs despite the pandemic. The Canadian Organization for Rare Disorders has warned that this threatens patient access to innovative medicines. The webinar will feature patient advocates discussing how the changes risk access to treatments for conditions like cystic fibrosis, pulmonary arterial hypertension, and rare diseases. It outlines the PMPRB's new regulations and price-setting mechanisms that will reduce drug prices in Canada to the lowest of other countries. Stakeholders are calling for pausing or collaborating on the changes to ensure patient access
Recommended
July 30 Webinar 3: Sharing and comparing feedback for the PMPRB Guidelines
July 30 Webinar 3: Sharing and comparing feedback for the PMPRB GuidelinesCanadian Organization for Rare Disorders
Webinar 3: Sharing and comparing feedback for the PMPRB Guidelines – July 30, 2020 at 12PM – 1PM EDT. Specialty Drugs for Hepatitis C, Multiple Sclerosis and Cancer Drove New Bran...
The unprecedented $20.2Bn increase in spending on new brands contributed 6.1% points to overall 13.1% growth in 2014.
Webinar 3: Alternative Approaches to Innovative Drug Pricing
Webinar 3: Alternative Approaches to Innovative Drug PricingCanadian Organization for Rare Disorders
The document discusses the proposed changes to Canada's Patented Medicine Prices Review Board (PMPRB) regulations and their potential impacts. It begins with concerns over implementing drastic price reductions for new prescription medicines during the COVID-19 pandemic. It then provides an overview of the webinar topics, which include perspectives on alternative drug pricing approaches and implications of the PMPRB changes. The changes would lower Canada's drug prices significantly by changing the comparator countries used to set maximum prices and introducing new factors to unilaterally set maximum rebated prices. There are concerns this could reduce patient access to innovative medicines, especially for rare diseases.Webinar 1: Has the PMPRB removed the obstacles to access in its Guidelines?
Webinar 1: Has the PMPRB removed the obstacles to access in its Guidelines?Canadian Organization for Rare Disorders
Summer 2020 PMPRB Webinar Series
Has the PMPRB removed the obstacles to access in its Guidelines? Thursday, June 25, 2020 12PM - 1PM EDTWebinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?Canadian Organization for Rare Disorders
CORD Spring 2020 Webinar Series
Webinar 2: Drug Launches: What Influences the Decision to Deploy New Medicines?Increasing Numbers of Launches and Growth in Spending on Specialty Products i...
The specialty products share of the R&D pipeline has increased 9% in the past decade, driven by drugs targeting cancer, nervous system disorders, infectious diseases, diabetes and respiratory disorders.
Unpacking the OHIP+ pharmacare plan for kids & youth in Ontario
Listeners participated in a live panel session addressing OHIP+, the recently announced expansion of the Ontario drug program to cover young people who are younger than 25 years-old.
Webinar 1: Patients Speak Out
The document summarizes a webinar on the changes to Canada's Patented Medicine Prices Review Board (PMPRB) and its potential negative impacts. It notes that the PMPRB is implementing drastic price reductions for new drugs despite the pandemic. The Canadian Organization for Rare Disorders has warned that this threatens patient access to innovative medicines. The webinar will feature patient advocates discussing how the changes risk access to treatments for conditions like cystic fibrosis, pulmonary arterial hypertension, and rare diseases. It outlines the PMPRB's new regulations and price-setting mechanisms that will reduce drug prices in Canada to the lowest of other countries. Stakeholders are calling for pausing or collaborating on the changes to ensure patient access
Health Canada calls for new tools to control drug prices: what will it mean ...
Health Canada calls for new tools to control drug prices: what will it mean ...Canadian Cancer Survivor Network
The Canadian Cancer Survivor Network is pleased to offer a webinar titled “Health Canada calls for new tools to control drug prices: what will it mean for patients?”. This webinar will summarize the various pharmaceutical pricing reforms recently announced by federal health minister Dr. Jane Philpott and examine their potential effects on patient access to new innovations.How Changes to the PMPRB Could Affect Patients' Access to Drugs
This webinar will introduce you to the Patented Medicine Prices Review Board (PMPRB), how they regulate drug pricing in Canada and the proposed changes that will affect cancer patients.
Projected impact of demographic change on the demand for pharmaceuticals in I...
Projected impact of demographic change on the demand for pharmaceuticals in I...Irish Pharmaceutical Healthcare Association (IPHA)
Presentation delivered by Dr Kathleen Bennett, Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St James’s Hospital at the Irish Pharmaceutical Healthcare Association Meeting 2009.A User’s Perspective: ACMG Guidelines for CNVs in VSClinical
Our last webcast introduced the newest features of VarSeq that will be included in our upcoming release. After a serious developmental effort, we are excited to announce one of these being the integration of ACMG Guidelines for CNVs!
VarSeq is not only the tertiary environment to filter through your imported SNVs and indels from any VCF file, but also includes robust and proven capabilities of CNV detection and clinical variant interpretation. With our upcoming release, users will be able to leverage an automated CNV ACMG classification filter that is paired with the CNV evaluation in the VSClinical interpretation hub. This webcast will expose attendees to literature reinforcing the quality of our CNV caller, as well as showing examples of CNV analysis to demonstrate how this tool can streamline the analysis process. In this webcast, we will cover:
Describing the new CNV guidelines and how Golden Helix tackles their complexity
Assessing CNV impact on Gene and Gene Dosage
Cited literature referencing the accuracy of VarSeq’s CNV calling
Product demonstrations of VSClinical’s CNV interpretation/classification and final report functionalities
Manually traversing the guidelines and classification process is fundamentally complex with multiple criteria considerations, collecting any necessary caveats, and bulk literature review just to name a few. It is our goal to simplify and streamline this process without losing user-control of final results or overlooking any crucial criteria components necessary for final classification. We hope you will join us to see how this is accomplished as we explore the ACMG CNV Guidelines within VSClinical from the user’s perspective!
Oncologics Spending Reached $43.4 billion in 2014
Oncologics led all classes in spending in 2014 with $32.3Bn in spending, or $43.4Bn including supportive care treatments.
Learn about the Canadian Association of Provincial Cancer Agencies (CAPCA) fr...
Learn about the Canadian Association of Provincial Cancer Agencies (CAPCA) fr...Canadian Cancer Survivor Network
CAPCA wants to make sure that patients have access to innovative and effective cancer treatments, and Heather Logan, ED of CAPCA, will explain how CAPCA is going to do this and answer your questions about the process. This webinar will introduce you to CAPCA and its mandate and to the new pan-Canadian Cancer Drug Funding Sustainability Initiative (DFSI). The goal of DFSI is to ensure that patients continue to have access to innovative and effective cancer treatments, and that the cancer system is achieving maximum value for money invested.VSClinical: First Commercial Product to Integrate the Updated ACMG Guidelines...
As CNV detection has become widely adopted as a component of NGS testing, the demand has grown for an interpreting framework specific to CNVs in the context of rare and inherited disorders. Earlier this year, a ClinGen working group in collaboration with ACMG, published new guidelines for the interpreting and reporting of CNVs detected by NGS. We at Golden Helix have been hard at work expanding VSClinical to incorporate these new scoring and evaluation criteria for the interpretation and clinical reporting of CNVs alongside small variants in our popular guided workflow for following the ACMG guidelines. Please join us in this webinar as we preview the upcoming release of VarSeq with this major development. We will cover the following:
- The new CNV guidelines, the specialized criteria for gains and losses, and how VSClinical simplifies the scoring and interpretation process
- How VS-CNV and VSClinical provides a complete solution for clinical detection and interpretation of CNVs for NGS gene panels and exomes
- The number of CNV specific data sources curated and integrated into the automatic recommendation system
- VSClinical’s integrated Word-based template system for designing custom clinical reports that include quality summary information, coverage at exon and gene level, interpreted variants and CNVs, and patient-level results
We are excited to release this major update to VSClinical, incorporating many small feature enhancements and user requests alongside with the integration of the CNV guidelines. Please join us in this webinar to see how CNVs can be an integrated part of the analysis workflow for your clinical NGS tests.
Global orphan drug market outlook 2018
“Global Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to global orphan drug market:
Global & Regional Orphan Drug Market Overview
Orphan Drug Designation Criteria Across Key Markets
Market Specific Reimbursement Policy & Regulatory Framework
Orphan Drug Pipeline by Phase, Orphan Designated Disease & Country
Competitive Landscape
FMCC 2016 Curbing Rx Drug Abuse Plenary by Daniel Blaney-Koen
The document discusses efforts to address the opioid epidemic in the United States, including:
- Increasing registration and use of prescription drug monitoring programs (PDMPs) to track opioid prescriptions.
- Reducing the stigma around both pain and substance use disorder to increase access to comprehensive treatment.
- Expanding access to naloxone to prevent overdose deaths and "Good Samaritan" legal protections.
- Ongoing education of physicians on safe opioid prescribing and alternative pain management strategies.
Transformations in Disease Treatment
More new medicines were launched in 2014 than in any year since 2001 and included 23 breakthrough therapies and orphan drugs.
FMCC 2016 Curbing Rx Drug Abuse Plenary by Sarah Chouinard
This document discusses strategies to curb prescription drug abuse, specifically opioid abuse, in West Virginia. It notes that West Virginia has the highest drug overdose mortality rate in the US and clinicians there write a high number of opioid prescriptions. It explores reasons for high prescribing rates and discusses solutions like improving education for patients and doctors, changing financial incentives, using prescription drug monitoring programs, and following CDC guidelines for safer opioid prescribing. Alternative therapies for pain management and the role of EDIE in monitoring patients and interfacing with PDMPs are also covered. The document advocates for internal referrals to pain specialists and multidisciplinary approaches to pain care.
Neil Dugdale sobi crdn summit 2017
This document summarizes a presentation given by Neil Dugdale of Sobi (Swedish Orphan Biovitrum) at the 2017 Cambridge Rare Disease Network Summit. The presentation discusses Sobi's work in rare diseases, including developing orphan drugs, partnering with patient advocacy groups, and donating factor therapy to expand treatment access for hemophilia in developing countries. Sobi aims to pioneer new approaches to rare disease management through multi-stakeholder engagement and community co-creation.
Biopharma Sales Resilience through Economic Recession
The document analyzes how sales of branded drug classes were impacted during the 2008/2009 economic recession. It hypothesizes that drug classes treating severe or acute conditions effectively with few alternatives would be most resilient. The analysis found biopharma generally more resilient than healthcare, though sales faced pressure from rising uninsured/Medicaid populations and tighter payer management. Drug classes addressing less severe issues or with low-cost options required ensuring continued access.
Myelin repair open science summit 07.31.10 v2
The document discusses the Myelin Repair Foundation's (MRF) mission to accelerate the discovery of treatments for multiple sclerosis (MS) by establishing a new paradigm for medical research. It outlines some of the inefficiencies of the current academic research and drug discovery system. The MRF aims to coordinate disease-specific research, protect intellectual property, and transition promising targets to clinical candidates more efficiently through its Accelerated Research Collaboration model. It summarizes the MRF's research progress and plans over its first five years and outlines strategies to further translate its discoveries.
Wed gs frieden
1) Prescription drug abuse in the U.S. has reached epidemic levels, with overdose deaths, opioid sales, and treatment admissions all rising in parallel since 1999. 2) To reverse the epidemic, efforts are needed to improve prescription drug monitoring programs (PDMPs), ensure safer opioid prescribing practices, expand access to treatment including buprenorphine, and support state-level prevention strategies. 3) Early evidence suggests that real-time, universal PDMPs; mandating their use; integrating them into electronic health records; and comprehensive laws can all help to reduce doctor shopping, opioid prescribing, and overdose deaths.
FMCC 2016 Curbing Rx Drug Abuse Plenary by Christopher Jones
The document summarizes the opioid epidemic in the United States and the response from the Department of Health and Human Services (HHS). It provides data showing that prescription opioids are the most commonly abused drugs and that opioid overdose deaths have increased significantly since 1999. The HHS Secretary launched an Opioid Initiative in 2015 focused on improving opioid prescribing practices, increasing access to naloxone to reverse overdoses, and expanding medication-assisted treatment for opioid use disorders. Partnerships with health organizations aim to train providers and increase access to prevention and treatment services. States like Washington that implemented comprehensive approaches have seen declines in overdose deaths and hospitalizations.
Medicines Use and Spending Shifts: A Review of the Use of Medicines
Growth in spending on medicines was higher in 2014 than any year since 2001, and
exceeded forecast overall healthcare spending growth for the first time since 2011.
As 2014 was also a landmark year in the implementation of the Affordable Care Act,
understanding the specific drivers of medicine spending growth is important for decisionmakers
across the healthcare system.
In this report we bring together several perspectives on 2014: total system spending on
medicines at an aggregate and segmented level; the evolution of healthcare demand, delivery
and payment systems; patient out-of-pocket costs for medical and pharmacy benefits including
retail prescription co-pays; and transformations in disease treatment resulting from newly
approved medicines.
Henry Spiller edited
This document discusses the use of poison center data to track trends in prescription drug abuse and overdoses. It shows that between 1999-2011, prescription opioid exposures reported to poison centers increased over 150% in the US and 164% in Kentucky. Specific opioids like oxycodone, hydrocodone, and tramadol also increased substantially. Poison center data can provide real-time surveillance to identify emerging problems and formulate strategies to address them.
Roadmap to Optimal Drug Access (Neil Palmer, PDCI) June 14, 2017
Roadmap to Optimal Drug Access (Neil Palmer, PDCI) June 14, 2017Canadian Organization for Rare Disorders
The document discusses approaches to drug pricing and access in various countries. It provides details on Health Canada's proposal for expanded international reference pricing, including the criteria for selecting reference countries. The document also examines the impact of international reference pricing on product introduction delays and launch sequencing. It analyzes mechanisms for price setting and reimbursement across different countries. Finally, it touches on reservation prices in negotiations and Germany's multi-stage process for drug reimbursement decisions.CORD Rare Disease Patient Survey
The survey found that patients with rare diseases face long delays in diagnosis, seeing multiple doctors and receiving misdiagnoses. At the time of diagnosis, many patients report not receiving enough information or not understanding what they were told. Most respondents feel that general practitioners, pediatricians and even specialists lack adequate knowledge about rare diseases. Access to treatment, specialists and support is also limited, and the majority of patients incur significant personal costs for care of their rare disease, averaging $14,400 annually outside Quebec.
Pharma, care and social media how to gain partnership in care
This document discusses how pharmaceutical companies can build partnerships in healthcare through the use of social media. It notes that pharmaceutical marketing faces increased scrutiny and regulation. To gain trust, companies should listen more than promote and be transparent. The document suggests moving from a product-focused to a patient-centered approach through social media engagement. Specifically, pharmaceutical companies could collaborate with healthcare providers and patients to co-create experiences that improve health outcomes.
Make In India – Healthcare Reforms, Insurance, Innovations, Investments & Inf...
7th Annual Pharmaceutical Leadership Summit & Pharmaleaders Business Leadership Awards 2014
Friday, 26th December, Hotel Sahara Star, Mumbai, India
Make In India – Healthcare Reforms
Insurance,Innovations,Investments & Infrastructure
“Empowering India’s Developing Healthcare System”
Investing the Healthcare Solutions of Tomorrow in difficult Times
More Related Content
What's hot
Health Canada calls for new tools to control drug prices: what will it mean ...
Health Canada calls for new tools to control drug prices: what will it mean ...Canadian Cancer Survivor Network
The Canadian Cancer Survivor Network is pleased to offer a webinar titled “Health Canada calls for new tools to control drug prices: what will it mean for patients?”. This webinar will summarize the various pharmaceutical pricing reforms recently announced by federal health minister Dr. Jane Philpott and examine their potential effects on patient access to new innovations.How Changes to the PMPRB Could Affect Patients' Access to Drugs
This webinar will introduce you to the Patented Medicine Prices Review Board (PMPRB), how they regulate drug pricing in Canada and the proposed changes that will affect cancer patients.
Projected impact of demographic change on the demand for pharmaceuticals in I...
Projected impact of demographic change on the demand for pharmaceuticals in I...Irish Pharmaceutical Healthcare Association (IPHA)
Presentation delivered by Dr Kathleen Bennett, Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St James’s Hospital at the Irish Pharmaceutical Healthcare Association Meeting 2009.A User’s Perspective: ACMG Guidelines for CNVs in VSClinical
Our last webcast introduced the newest features of VarSeq that will be included in our upcoming release. After a serious developmental effort, we are excited to announce one of these being the integration of ACMG Guidelines for CNVs!
VarSeq is not only the tertiary environment to filter through your imported SNVs and indels from any VCF file, but also includes robust and proven capabilities of CNV detection and clinical variant interpretation. With our upcoming release, users will be able to leverage an automated CNV ACMG classification filter that is paired with the CNV evaluation in the VSClinical interpretation hub. This webcast will expose attendees to literature reinforcing the quality of our CNV caller, as well as showing examples of CNV analysis to demonstrate how this tool can streamline the analysis process. In this webcast, we will cover:
Describing the new CNV guidelines and how Golden Helix tackles their complexity
Assessing CNV impact on Gene and Gene Dosage
Cited literature referencing the accuracy of VarSeq’s CNV calling
Product demonstrations of VSClinical’s CNV interpretation/classification and final report functionalities
Manually traversing the guidelines and classification process is fundamentally complex with multiple criteria considerations, collecting any necessary caveats, and bulk literature review just to name a few. It is our goal to simplify and streamline this process without losing user-control of final results or overlooking any crucial criteria components necessary for final classification. We hope you will join us to see how this is accomplished as we explore the ACMG CNV Guidelines within VSClinical from the user’s perspective!
Oncologics Spending Reached $43.4 billion in 2014
Oncologics led all classes in spending in 2014 with $32.3Bn in spending, or $43.4Bn including supportive care treatments.
Learn about the Canadian Association of Provincial Cancer Agencies (CAPCA) fr...
Learn about the Canadian Association of Provincial Cancer Agencies (CAPCA) fr...Canadian Cancer Survivor Network
CAPCA wants to make sure that patients have access to innovative and effective cancer treatments, and Heather Logan, ED of CAPCA, will explain how CAPCA is going to do this and answer your questions about the process. This webinar will introduce you to CAPCA and its mandate and to the new pan-Canadian Cancer Drug Funding Sustainability Initiative (DFSI). The goal of DFSI is to ensure that patients continue to have access to innovative and effective cancer treatments, and that the cancer system is achieving maximum value for money invested.VSClinical: First Commercial Product to Integrate the Updated ACMG Guidelines...
As CNV detection has become widely adopted as a component of NGS testing, the demand has grown for an interpreting framework specific to CNVs in the context of rare and inherited disorders. Earlier this year, a ClinGen working group in collaboration with ACMG, published new guidelines for the interpreting and reporting of CNVs detected by NGS. We at Golden Helix have been hard at work expanding VSClinical to incorporate these new scoring and evaluation criteria for the interpretation and clinical reporting of CNVs alongside small variants in our popular guided workflow for following the ACMG guidelines. Please join us in this webinar as we preview the upcoming release of VarSeq with this major development. We will cover the following:
- The new CNV guidelines, the specialized criteria for gains and losses, and how VSClinical simplifies the scoring and interpretation process
- How VS-CNV and VSClinical provides a complete solution for clinical detection and interpretation of CNVs for NGS gene panels and exomes
- The number of CNV specific data sources curated and integrated into the automatic recommendation system
- VSClinical’s integrated Word-based template system for designing custom clinical reports that include quality summary information, coverage at exon and gene level, interpreted variants and CNVs, and patient-level results
We are excited to release this major update to VSClinical, incorporating many small feature enhancements and user requests alongside with the integration of the CNV guidelines. Please join us in this webinar to see how CNVs can be an integrated part of the analysis workflow for your clinical NGS tests.
Global orphan drug market outlook 2018
“Global Orphan Drug Market Outlook 2018” research report by KuicK Research comprehensive insight on following developments related to global orphan drug market:
Global & Regional Orphan Drug Market Overview
Orphan Drug Designation Criteria Across Key Markets
Market Specific Reimbursement Policy & Regulatory Framework
Orphan Drug Pipeline by Phase, Orphan Designated Disease & Country
Competitive Landscape
FMCC 2016 Curbing Rx Drug Abuse Plenary by Daniel Blaney-Koen
The document discusses efforts to address the opioid epidemic in the United States, including:
- Increasing registration and use of prescription drug monitoring programs (PDMPs) to track opioid prescriptions.
- Reducing the stigma around both pain and substance use disorder to increase access to comprehensive treatment.
- Expanding access to naloxone to prevent overdose deaths and "Good Samaritan" legal protections.
- Ongoing education of physicians on safe opioid prescribing and alternative pain management strategies.
Transformations in Disease Treatment
More new medicines were launched in 2014 than in any year since 2001 and included 23 breakthrough therapies and orphan drugs.
FMCC 2016 Curbing Rx Drug Abuse Plenary by Sarah Chouinard
This document discusses strategies to curb prescription drug abuse, specifically opioid abuse, in West Virginia. It notes that West Virginia has the highest drug overdose mortality rate in the US and clinicians there write a high number of opioid prescriptions. It explores reasons for high prescribing rates and discusses solutions like improving education for patients and doctors, changing financial incentives, using prescription drug monitoring programs, and following CDC guidelines for safer opioid prescribing. Alternative therapies for pain management and the role of EDIE in monitoring patients and interfacing with PDMPs are also covered. The document advocates for internal referrals to pain specialists and multidisciplinary approaches to pain care.
Neil Dugdale sobi crdn summit 2017
This document summarizes a presentation given by Neil Dugdale of Sobi (Swedish Orphan Biovitrum) at the 2017 Cambridge Rare Disease Network Summit. The presentation discusses Sobi's work in rare diseases, including developing orphan drugs, partnering with patient advocacy groups, and donating factor therapy to expand treatment access for hemophilia in developing countries. Sobi aims to pioneer new approaches to rare disease management through multi-stakeholder engagement and community co-creation.
Biopharma Sales Resilience through Economic Recession
The document analyzes how sales of branded drug classes were impacted during the 2008/2009 economic recession. It hypothesizes that drug classes treating severe or acute conditions effectively with few alternatives would be most resilient. The analysis found biopharma generally more resilient than healthcare, though sales faced pressure from rising uninsured/Medicaid populations and tighter payer management. Drug classes addressing less severe issues or with low-cost options required ensuring continued access.
Myelin repair open science summit 07.31.10 v2
The document discusses the Myelin Repair Foundation's (MRF) mission to accelerate the discovery of treatments for multiple sclerosis (MS) by establishing a new paradigm for medical research. It outlines some of the inefficiencies of the current academic research and drug discovery system. The MRF aims to coordinate disease-specific research, protect intellectual property, and transition promising targets to clinical candidates more efficiently through its Accelerated Research Collaboration model. It summarizes the MRF's research progress and plans over its first five years and outlines strategies to further translate its discoveries.
Wed gs frieden
1) Prescription drug abuse in the U.S. has reached epidemic levels, with overdose deaths, opioid sales, and treatment admissions all rising in parallel since 1999. 2) To reverse the epidemic, efforts are needed to improve prescription drug monitoring programs (PDMPs), ensure safer opioid prescribing practices, expand access to treatment including buprenorphine, and support state-level prevention strategies. 3) Early evidence suggests that real-time, universal PDMPs; mandating their use; integrating them into electronic health records; and comprehensive laws can all help to reduce doctor shopping, opioid prescribing, and overdose deaths.
FMCC 2016 Curbing Rx Drug Abuse Plenary by Christopher Jones
The document summarizes the opioid epidemic in the United States and the response from the Department of Health and Human Services (HHS). It provides data showing that prescription opioids are the most commonly abused drugs and that opioid overdose deaths have increased significantly since 1999. The HHS Secretary launched an Opioid Initiative in 2015 focused on improving opioid prescribing practices, increasing access to naloxone to reverse overdoses, and expanding medication-assisted treatment for opioid use disorders. Partnerships with health organizations aim to train providers and increase access to prevention and treatment services. States like Washington that implemented comprehensive approaches have seen declines in overdose deaths and hospitalizations.
Medicines Use and Spending Shifts: A Review of the Use of Medicines
Growth in spending on medicines was higher in 2014 than any year since 2001, and
exceeded forecast overall healthcare spending growth for the first time since 2011.
As 2014 was also a landmark year in the implementation of the Affordable Care Act,
understanding the specific drivers of medicine spending growth is important for decisionmakers
across the healthcare system.
In this report we bring together several perspectives on 2014: total system spending on
medicines at an aggregate and segmented level; the evolution of healthcare demand, delivery
and payment systems; patient out-of-pocket costs for medical and pharmacy benefits including
retail prescription co-pays; and transformations in disease treatment resulting from newly
approved medicines.
Henry Spiller edited
This document discusses the use of poison center data to track trends in prescription drug abuse and overdoses. It shows that between 1999-2011, prescription opioid exposures reported to poison centers increased over 150% in the US and 164% in Kentucky. Specific opioids like oxycodone, hydrocodone, and tramadol also increased substantially. Poison center data can provide real-time surveillance to identify emerging problems and formulate strategies to address them.
Roadmap to Optimal Drug Access (Neil Palmer, PDCI) June 14, 2017
Roadmap to Optimal Drug Access (Neil Palmer, PDCI) June 14, 2017Canadian Organization for Rare Disorders
The document discusses approaches to drug pricing and access in various countries. It provides details on Health Canada's proposal for expanded international reference pricing, including the criteria for selecting reference countries. The document also examines the impact of international reference pricing on product introduction delays and launch sequencing. It analyzes mechanisms for price setting and reimbursement across different countries. Finally, it touches on reservation prices in negotiations and Germany's multi-stage process for drug reimbursement decisions.CORD Rare Disease Patient Survey
The survey found that patients with rare diseases face long delays in diagnosis, seeing multiple doctors and receiving misdiagnoses. At the time of diagnosis, many patients report not receiving enough information or not understanding what they were told. Most respondents feel that general practitioners, pediatricians and even specialists lack adequate knowledge about rare diseases. Access to treatment, specialists and support is also limited, and the majority of patients incur significant personal costs for care of their rare disease, averaging $14,400 annually outside Quebec.
What's hot (20)
Health Canada calls for new tools to control drug prices: what will it mean ...
Health Canada calls for new tools to control drug prices: what will it mean ...
How Changes to the PMPRB Could Affect Patients' Access to Drugs
How Changes to the PMPRB Could Affect Patients' Access to Drugs
Projected impact of demographic change on the demand for pharmaceuticals in I...
Projected impact of demographic change on the demand for pharmaceuticals in I...
A User’s Perspective: ACMG Guidelines for CNVs in VSClinical
A User’s Perspective: ACMG Guidelines for CNVs in VSClinical
Learn about the Canadian Association of Provincial Cancer Agencies (CAPCA) fr...
Learn about the Canadian Association of Provincial Cancer Agencies (CAPCA) fr...
VSClinical: First Commercial Product to Integrate the Updated ACMG Guidelines...
VSClinical: First Commercial Product to Integrate the Updated ACMG Guidelines...
FMCC 2016 Curbing Rx Drug Abuse Plenary by Daniel Blaney-Koen
FMCC 2016 Curbing Rx Drug Abuse Plenary by Daniel Blaney-Koen
FMCC 2016 Curbing Rx Drug Abuse Plenary by Sarah Chouinard
FMCC 2016 Curbing Rx Drug Abuse Plenary by Sarah Chouinard
Biopharma Sales Resilience through Economic Recession
Biopharma Sales Resilience through Economic Recession
FMCC 2016 Curbing Rx Drug Abuse Plenary by Christopher Jones
FMCC 2016 Curbing Rx Drug Abuse Plenary by Christopher Jones
Medicines Use and Spending Shifts: A Review of the Use of Medicines
Medicines Use and Spending Shifts: A Review of the Use of Medicines
Roadmap to Optimal Drug Access (Neil Palmer, PDCI) June 14, 2017
Roadmap to Optimal Drug Access (Neil Palmer, PDCI) June 14, 2017
Viewers also liked
Pharma, care and social media how to gain partnership in care
This document discusses how pharmaceutical companies can build partnerships in healthcare through the use of social media. It notes that pharmaceutical marketing faces increased scrutiny and regulation. To gain trust, companies should listen more than promote and be transparent. The document suggests moving from a product-focused to a patient-centered approach through social media engagement. Specifically, pharmaceutical companies could collaborate with healthcare providers and patients to co-create experiences that improve health outcomes.
Make In India – Healthcare Reforms, Insurance, Innovations, Investments & Inf...
7th Annual Pharmaceutical Leadership Summit & Pharmaleaders Business Leadership Awards 2014
Friday, 26th December, Hotel Sahara Star, Mumbai, India
Make In India – Healthcare Reforms
Insurance,Innovations,Investments & Infrastructure
“Empowering India’s Developing Healthcare System”
Investing the Healthcare Solutions of Tomorrow in difficult Times
US Healthcare Reform and Impact On Pharma and Healthcare IT Companies
US Healthcare Reform and Its Impact on Pharma and Healthcare Companies:
Implications Current and Future
Presented at the Edison Ventures Pharma and Healthcare Business Solutions Executive Meeting Lawrenceville, NJ
April 20, 2010
10 Essential Facts About Medicaer and Prescription Drug Spending
The document provides data on US prescription drug spending from 2005 to 2024. It shows that total spending has increased from $205 billion in 2005 to a projected $528 billion in 2024, with most of the increase coming from private health insurance, Medicare, and Medicaid. It also provides breakdowns of Medicare prescription drug spending and projections for growth rates in per capita Medicare spending through 2025. Additionally, it gives data on out-of-pocket costs for Medicare beneficiaries and public opinion on policies to lower drug prices.
Healthcare in the US - Pratik Shrestha
This document provides an overview of the U.S. healthcare system. It discusses key players like providers, insurers, and patients. It notes that healthcare is a trillion dollar industry, comprising hospitals, medical practices, and insurance companies. The document also outlines government programs like Medicare and Medicaid, different types of health insurance plans, and managed care organizations. Finally, it summarizes some electronic transactions used in healthcare like claims submission and response.
Pharmaceutical Mergers Acquisitions in the U.S
Since 2010, approximately 200 pharmaceutical and biotech deals have taken place per year in the United States. In 2014, only 182 major deals took place, lower than average (~190).
However, 2014 surpassed the combined value of deals from 2011-2013 ($178bn) and saw over $200bn in mergers and acquisitions, a 300% increase from the previous year.
How do we see the healthcare's digital future and its impact on our lives?
"Healthcare is undergoing major changes spurred on by, but not limited to, technology.
Digitalisation is changing the way we think about health, what taking care of it really entails, our personal role in healthcare systems and the way we interact with technology in the context of health.
In many ways, we are entering a post-institutional age of increased personal responsibility, which presents healthcare service providers and other players in the field with major opportunities and great risks. Technology has the potential to empower people and help them become more active in the management of their and their families’ health. This will change the relationship of the patient and the caregiver in profound ways." Mirkka Länsisalo
A co-creation with Mirkka Läansisalo and Sala Heinänen, at Futurice.
Viewers also liked (7)
Pharma, care and social media how to gain partnership in care
Pharma, care and social media how to gain partnership in care
Make In India – Healthcare Reforms, Insurance, Innovations, Investments & Inf...
Make In India – Healthcare Reforms, Insurance, Innovations, Investments & Inf...
US Healthcare Reform and Impact On Pharma and Healthcare IT Companies
US Healthcare Reform and Impact On Pharma and Healthcare IT Companies
10 Essential Facts About Medicaer and Prescription Drug Spending
10 Essential Facts About Medicaer and Prescription Drug Spending
How do we see the healthcare's digital future and its impact on our lives?
How do we see the healthcare's digital future and its impact on our lives?
Similar to Canadian Generic Market
10 Essential Facts About Medicare and Prescription Drug Spending
Total US prescription drug spending is projected to grow from $298 billion in 2014 to $597 billion in 2025. Medicare spending on prescription drugs grew from $205 billion in 2005 to $341 billion in 2016 and is projected to reach $597 billion in 2025. The top 10 drugs by Medicare spending in 2015 accounted for 79% of total Medicare Part D spending, with Harvoni alone accounting for 5.1% of spending. Average annual growth in Medicare Part D spending per enrollee is projected to be 15% from 2016 to 2026.
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...Life Sciences Network marcus evans
This document summarizes a presentation on strategies for boosting pharmaceutical innovation given by Kenneth Kaitin. It discusses the current challenging environment for drug development, including expiring patents, competitive markets, and high costs. Drug development times are long with low success rates, driving costs upwards. Oncology has become a major focus of R&D investment. The presentation proposes ways to stimulate innovation in areas of high medical need but low commercial appeal, such as through regulatory and legislative incentives.The Medicare Modernization Act and Medicare Part B Covered Drug Utilization a...
The Medicare Modernization Act and Medicare Part B Covered Drug Utilization a...Leonard Davis Institute of Health Economics
The document analyzes trends in Medicare Part B drug utilization and spending from 2002-2006, during which time the Medicare Modernization Act was passed in 2003. This led to changes in reimbursement rates for Part B drugs. The analysis found that while the number of Part B drug users and claims increased over this period, the rate of growth in spending remarkably slowed after the MMA despite increases in utilization. The rankings of the top 20 drugs by spending changed, with some dropping substantially due to decreased reimbursement rates under the MMA.Prescription Medicines: Costs in Context June 2022
This document discusses prescription drug costs and spending in the United States healthcare system. It notes that prescription drugs account for only 14% of total healthcare spending and that spending on drugs has remained stable as a share of overall costs. While new treatments have improved patient outcomes for conditions like cancer, overall drug costs are not expected to significantly impact total healthcare expenditures. The document also examines factors that influence patient affordability and access to medicines, such as the role of pharmacy benefit managers and hospitals.
Opportunities & Challenges in West Africa's (Ghana & Nigeria) Healthcare and ...
Opportunities & Challenges in West Africa's (Ghana & Nigeria) Healthcare and ...Aiswariya Chidambaram
This presentation made at the Pharma Insights Briefing session of CPhI Worldwide 2014, Paris, provides information on the market opportunities of
the fastest growing pharmaceutical markets in Africa: Ghana and Nigeria.
• Market sizing and Growth Trends
• Key Merger, Acquisition and Partnership Assessment
• Market Drivers and Challenges
• Pharmaceutical Procurement, Supply, Distribution and Retail
• SWOT and PESTLE Analysis
• Competitive Landscape Analysis
• Therapeutic Area Growth Analysis
• Strategic RecommendationsPrescription Medicines: Costs in Context - May 2023
This document discusses the costs of prescription medicines in the United States. It notes that while new medicines and treatments are improving patient outcomes, prescription drug costs make up a small and stable portion of total health care spending. However, the document also outlines ways that other entities like pharmacy benefit managers, hospitals, and insurers receive an increasing share of spending on brand medicines through rebates, fees, and price markups, shifting more costs onto patients. It calls for reforms to make medicines more affordable and ensure patients benefit from industry savings.
Prescription Medicines: Costs in Context - June 2022
The document summarizes information about prescription drug costs and spending in the United States. It notes that while new breakthrough medicines and treatments are being approved, prescription drug spending accounts for a small and stable share of total health care spending. Though net prices of brand name drugs have remained flat in recent years, other entities like PBMs, insurers, and hospitals receive an increasing portion of total drug spending. The document argues for reforms to make medicines more affordable and accessible for patients.
Prescription Medicines: Costs in Context - August2022
This document discusses prescription drug costs and spending in the United States healthcare system. It notes that while new breakthrough medicines are improving patient outcomes, prescription drug spending accounts for only a small portion of total healthcare spending that has remained stable in recent years. However, the document also outlines challenges patients face with rising out-of-pocket costs due to non-transparent business practices of middlemen like PBMs and hospitals that inflate list prices. It advocates for policy reforms to lower patient costs and ensure access to needed medicines.
What's next for the Patented Medicine Prices Review Board (PMPRB)?
The document summarizes the changes made by the Patented Medicine Prices Review Board (PMPRB) to lower drug prices in Canada. It analyzes the impact of replacing reference countries in the price test with lower-cost nations. It presents a case study showing a rare disease drug may no longer be price compliant under new rules. It concludes drug companies face greater uncertainty and risk in launching new medicines in Canada, which could delay access for patients and the potential for a national pharmacare program.
Global gene therapy market & pipeline insight
“Global Gene Therapy Market & Pipeline Insight” Market Highlight:
Gene Therapy Market Overview
Significance of Gene Therapy in Cancer Therapeutics
Current Applications of Gene Therapy to Cancer Treatment
Gene Therapy Market Dynamics: Drivers, Challenges & Future Outlook
FDA & AMA Guidelines for Gene Therapy
Gene Therapy Pipeline by Phase, Indications, Country & Company
Gene Therapy Pipeline: 246 Drugs
Marketed Gene Therapy: 2 (Gendicine & Rexin-G)
Cancer Gene Therapy Pipeline: 69 Drugs
Payer Trends in the ASC Industry
This presentations, "Payer Trends in the ASC Industry,” covers
Overall national trends
Hospital v. ASC comparisons
ASC “value pitch” to payers
Price transparency—defining price
Prescription Medicines Costs in Context March 2022
This document discusses trends in prescription drug costs and spending in the United States. It notes that 60 new medicines were approved by the FDA in 2021 for cancer, hemophilia, and COVID. While brand drug prices declined slightly in 2020, overall drug spending grew modestly. Most drug spending goes to health insurers, pharmacy benefit managers, and other entities rather than drug manufacturers. The majority of drugs dispensed are generics, which provide billions in savings each year. The document argues that while drug spending is projected to increase at a similar rate as overall healthcare costs, patients still face high out-of-pocket costs due to deductibles, coinsurance, and other cost-sharing policies by insurers.
Strategic alternatives
Big Pharma is facing a crisis as many blockbuster drugs are going off-patent and the pipeline of new drugs is weak. R&D spending has doubled over the past decade but productivity has declined, with fewer new drugs approved despite higher costs. Alternative strategies such as mergers and acquisitions, in-licensing, and partnerships have had mixed results in addressing the pipeline problem. The document discusses challenges in drug development and strategies the pharmaceutical industry has used to boost R&D productivity.
Pharma industry: present landscape and main trends
Presentación realizada en la 16 International Conference of Pharmaceutical Medicine and X Congreso AMIFE 2012, Barcelona, 14-16 noviembre, 2012
Prescription Medicines Costs in Context April 2021
This document discusses the costs of prescription medicines in the United States. It notes that while brand medicine prices have risen 1.7% in 2019, in line with inflation, many patients still struggle with costs. It also discusses that prescription medicines make up only 14% of total healthcare spending in the US. Finally, it summarizes efforts by PhRMA to make medicines more affordable and accessible for patients.
Payer Trends in the ASC Industry
A presentation discussing overall national trends, hospital v. ASC comparisons, ASC “value pitch” to payers, defining price through transparency
Laine statewide dd meeting bpm mailings 4 13
The document summarizes a behavioral pharmacy management program in Missouri that analyzes Medicaid claims data to identify quality indicators related to psychotropic medication prescribing practices at state habilitation centers. Mailings are sent to the centers listing the numbers of patients meeting various quality indicators and benchmark reports compare prescribing across centers over time. The program found increases in the numbers of patients prescribed multiple psychotropic medications or antipsychotics.
Breaking the barriers in the management of neovascular AMD
The document summarizes key details from two phase 3 clinical trials called HAWK and HARRIER that compared the anti-VEGF drug brolucizumab to aflibercept for treating neovascular age-related macular degeneration (nAMD). The trials involved over 1700 patients across multiple international sites. Patients were randomly assigned to receive either brolucizumab 3mg or 6mg, or aflibercept 2mg. The primary endpoint was change in vision from baseline at week 48, with assessments continuing through week 96. Brolucizumab demonstrated non-inferiority to aflibercept and an ability to be dosed as infrequently as every 12 weeks after the initial
Wall Street Mastermind Sector Spotlight - Healthcare (September 2023)
Here are the contents of this month's Healthcare Sector Spotlight:
1. Trading and M&A Comps
2. Obesity Drug Market
3. Illumina/Grail Debacle
4. Royalty Finance
5. J&J Consumer Health IPO
Petterson2
This document discusses the distribution of various primary care providers across rural and urban areas in the United States. It finds that rural areas tend to have fewer family physicians, pediatricians, physician assistants, nurse practitioners, and certified nurse midwives per capita compared to urban areas. Several states and local areas are also identified as having shortages or surpluses of primary care providers based on benchmark ratios. The document concludes by discussing some options for expanding the primary care workforce in rural areas, such as increasing funding for programs that incentivize providers to practice in underserved locations.
Similar to Canadian Generic Market (20)
10 Essential Facts About Medicare and Prescription Drug Spending
10 Essential Facts About Medicare and Prescription Drug Spending
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
The Medicare Modernization Act and Medicare Part B Covered Drug Utilization a...
The Medicare Modernization Act and Medicare Part B Covered Drug Utilization a...
Prescription Medicines: Costs in Context June 2022
Prescription Medicines: Costs in Context June 2022
Opportunities & Challenges in West Africa's (Ghana & Nigeria) Healthcare and ...
Opportunities & Challenges in West Africa's (Ghana & Nigeria) Healthcare and ...
Prescription Medicines: Costs in Context - May 2023
Prescription Medicines: Costs in Context - May 2023
Prescription Medicines: Costs in Context - June 2022
Prescription Medicines: Costs in Context - June 2022
Prescription Medicines: Costs in Context - August2022
Prescription Medicines: Costs in Context - August2022
What's next for the Patented Medicine Prices Review Board (PMPRB)?
What's next for the Patented Medicine Prices Review Board (PMPRB)?
Prescription Medicines Costs in Context March 2022
Prescription Medicines Costs in Context March 2022
Pharma industry: present landscape and main trends
Pharma industry: present landscape and main trends
Prescription Medicines Costs in Context April 2021
Prescription Medicines Costs in Context April 2021
Breaking the barriers in the management of neovascular AMD
Breaking the barriers in the management of neovascular AMD
Wall Street Mastermind Sector Spotlight - Healthcare (September 2023)
Wall Street Mastermind Sector Spotlight - Healthcare (September 2023)
Recently uploaded
Cell Therapy Expansion and Challenges in Autoimmune Disease
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
ABDOMINAL TRAUMA in pediatrics part one.
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
NVBDCP.pptx Nation vector borne disease control program
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
share - Lions, tigers, AI and health misinformation, oh my!.pptx
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Efficacy of Avartana Sneha in Ayurveda
Avartana Sneha is a unique method of Preparation of Sneha Kalpana in Ayurveda, mainly it is indicated for the Vataja rogas.
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Learn about body grief and ways to cope with it. We will also explore methods to heal from this challenging experience.
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...chandankumarsmartiso
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel With 100% Satisfaction
Best Ayurvedic medicine for Gas and Indigestion
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxMGM SCHOOL/COLLEGE OF NURSING
Identification and nursing management of congenital malformations Recently uploaded (20)
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 8107221448 #ℂall #gIRL in Dehradun
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Part II - Body Grief: Losing parts of ourselves and our identity before, duri...
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...
Phone Us ❤8107221448❤ #ℂall #gIRLS In Dehradun By Dehradun @ℂall @Girls Hotel...
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
Canadian Generic Market
- 1. Overview of Canadian Generic Prescription Drug Market 12 months ending September 2007
- 2. 12 months ending September 2007 47.6% 19.8% 80.2% 52.4% The Canadian Prescription Drug Market Source:
- 3. Canadian Generic Prescription Drugstore & Hospital Market Source:
- 4. Generic Share of the Canadian Prescription Drug Market Source:
- 5. The Canadian Prescription Drug Market Source:
- 6. Growth Brand vs. Generic Drugstore & Hospital Sales Source:
- 7. Regional Market Share of Generic Sales 24.3% 22.7% 19.5% 15.7% Canada: 19.8% N.B. 24.7% N.S. 24.3% PEI & 24.8% Nfld. 20.9% 24.4% Source: IMS D&H Regional Nunavut Northwest Territories Yukon Territory 12 months ending September 2007
- 8. Generic Rx Penetration by Region 54.6% 56.7% 50.7% 52.0% 49.3% 51.3% 42.2% 43.0% Canada: MAT 09/07 47.6% QTR3 /07 49.1% N.B. 54.2% 56.4% N.S. 50.1% 51.9% PEI & 51.1% 53.3% Nfld. 49.6% 51.5% 54.2% 54.8% Source: IMS Compuscript Nunavut Northwest Territories Yukon Territory
- 9. Generic Rx Penetration by Region Source:
- 10. Ranking of Drugstore & Hospital Sales by Corporation Source:
- 11. Leading Products by Drugstore & Hospital Sales 12 months ending September 2007 Source: Top 15 products represent 22% of total ($’s) market
- 12. First time generics launched latest 12 months
- 13. Ranking of Retail Prescriptions by Corporation Source:
- 14. Canadian Generic Prescription Market 12 months ending September 2007 Source:
- 15. Ranking of Drugstore & Hospital Sales by Generic Manufacturer Source:
- 16. Ranking of Retail Prescriptions by Generic Manufacturer Source:
- 17. Percent Share of Canadian Generic Prescription $ Market Source: